New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery
Background Preoperative evaluation and perioperative management of cardiac disease in patients undergoing vascular surgery (VS) is important for patients and vascular surgeons. Recent evidence has emerged that has allowed us to develop contemporary paradigms for evaluating and managing coronary arte...
Gespeichert in:
| Veröffentlicht in: | Journal of vascular surgery 2010, Vol.51 (1), p.242-251 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | 1 |
| container_start_page | 242 |
| container_title | Journal of vascular surgery |
| container_volume | 51 |
| creator | Bauer, Stephen M., MD Cayne, Neal S., MD Veith, Frank J., MD |
| description | Background Preoperative evaluation and perioperative management of cardiac disease in patients undergoing vascular surgery (VS) is important for patients and vascular surgeons. Recent evidence has emerged that has allowed us to develop contemporary paradigms for evaluating and managing coronary artery disease in VS patients perioperatively. Methods The utility of stress testing, the role of preoperative coronary revascularization, the optimal use of β-blockers and statins, and the role of antiplatelet therapy in VS patients were reviewed in the literature. Results The revised Lee cardiac risk index, based on the number of risk factors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-dependent diabetes mellitus, renal failure, hypertension, and age >75) quantitates cardiac risk. Stress testing is not predictive of myocardial ischemia/infarction (MI) or death and is only recommended in patients with unstable angina or an active arrhythmia. Stress testing for patients with 0 to 2 risk factors delays VS up to 3 weeks. In high-risk patients (≥3 risk factors), it helps to identify patients who may develop myocardial ischemia and would benefit from a 30-day period to optimize medical therapy before VS. Stress testing and coronary catheterization do not predict which coronary artery to revascularize to prevent MI or death. Revascularization does not decrease MI or death rates at 1 month or 6 years. Although β-blocker treatment decreases cardiac risk with VS, timing and dosage (titration) influence outcomes, improper usage may increase stroke and death rate, and not all VS patients should be taking these drugs. Patients with ≥1 risk factor should be considered to begin a low dose β-blocker 1 month before VS. Preoperative statin use sharply decreases MI, stroke, and death perioperatively and long-term postoperatively. Conclusion Routine stress testing should not be performed before VS. The Lee index should be used to stratify risk in patients undergoing VS. Patients with ≥3 risk factors or active cardiac conditions should undergo stress testing, if VS can be delayed. All VS patients, except those with 0 risk factors, should be considered for a β-blocker (bisoprolol, 2.5-5 mg/d started 1 month before VS, titrated to a pulse |
| doi_str_mv | 10.1016/j.jvs.2009.08.087 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734265509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0741521409018199</els_id><sourcerecordid>734265509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-519099cb9d2982f9723eaaf4049d99992a524b9ee0152fe2dd0c5dca6b8b793a3</originalsourceid><addsrcrecordid>eNp9kt2K1TAQgIso7nH1AbyR3IhXPU7S9rRBEJbFP1j0Qr0OaTI9prZJTdrKPoWv7NRzcMELw8CE5Jv_ybKnHPYc-OFlv-_XtBcAcg8NSX0v23GQdX5oQN7PdlCXPK8ELy-yRyn1AJxXTf0wu-BSVqUUYpf9-og_mcUVhzCN6OfEnGfzN2RTxDBh1LNbkeGqh4WuwTPtLaN3d_c5aq-PuBmz0DETYvA63jIdZyRlXUKdcHM7Ef8nxOItxmNw_shWncwy6MjSEo_EP84edHpI-OSsL7Ovb998uX6f33x69-H66iY3ZQNzXnEJUppWWiEb0claFKh1V0IpraQjdCXKViICr0SHwlowlTX60DZtLQtdXGYvTn6nGH4smGY1umRwGLTHsCRVF6U4VBVIIvmJNDGkFLFTU3QjVag4qG0Mqlc0BrWNQUFDUpPNs7P3pR3R3lmc-07A8zNA9euhi9obl_5yRIiiKDdHr04cUi9Wh1ElQz00aF1EMysb3H_TeP2PtRmcdxTwO95i6sMSPTVZcZWEAvV525dtXUACbyjX4jepxb6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734265509</pqid></control><display><type>article</type><title>New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bauer, Stephen M., MD ; Cayne, Neal S., MD ; Veith, Frank J., MD</creator><creatorcontrib>Bauer, Stephen M., MD ; Cayne, Neal S., MD ; Veith, Frank J., MD</creatorcontrib><description>Background Preoperative evaluation and perioperative management of cardiac disease in patients undergoing vascular surgery (VS) is important for patients and vascular surgeons. Recent evidence has emerged that has allowed us to develop contemporary paradigms for evaluating and managing coronary artery disease in VS patients perioperatively. Methods The utility of stress testing, the role of preoperative coronary revascularization, the optimal use of β-blockers and statins, and the role of antiplatelet therapy in VS patients were reviewed in the literature. Results The revised Lee cardiac risk index, based on the number of risk factors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-dependent diabetes mellitus, renal failure, hypertension, and age >75) quantitates cardiac risk. Stress testing is not predictive of myocardial ischemia/infarction (MI) or death and is only recommended in patients with unstable angina or an active arrhythmia. Stress testing for patients with 0 to 2 risk factors delays VS up to 3 weeks. In high-risk patients (≥3 risk factors), it helps to identify patients who may develop myocardial ischemia and would benefit from a 30-day period to optimize medical therapy before VS. Stress testing and coronary catheterization do not predict which coronary artery to revascularize to prevent MI or death. Revascularization does not decrease MI or death rates at 1 month or 6 years. Although β-blocker treatment decreases cardiac risk with VS, timing and dosage (titration) influence outcomes, improper usage may increase stroke and death rate, and not all VS patients should be taking these drugs. Patients with ≥1 risk factor should be considered to begin a low dose β-blocker 1 month before VS. Preoperative statin use sharply decreases MI, stroke, and death perioperatively and long-term postoperatively. Conclusion Routine stress testing should not be performed before VS. The Lee index should be used to stratify risk in patients undergoing VS. Patients with ≥3 risk factors or active cardiac conditions should undergo stress testing, if VS can be delayed. All VS patients, except those with 0 risk factors, should be considered for a β-blocker (bisoprolol, 2.5-5 mg/d started 1 month before VS, titrated to a pulse <70 beats/min and a systolic blood pressure ≥120 mm Hg). Intermediate risk factors may not require aggressive heart rate control but simply maintenance on a low-dose β-blocker. Statins should be started (ideally 30 days) before all VS using long-acting formulations such as fluvastatin (80 mg/d) for patients unable to take oral medication.</description><identifier>ISSN: 0741-5214</identifier><identifier>EISSN: 1097-6809</identifier><identifier>DOI: 10.1016/j.jvs.2009.08.087</identifier><identifier>PMID: 19954922</identifier><identifier>CODEN: JVSUES</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Algorithms ; American Heart Association ; Biological and medical sciences ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Cardiovascular system ; Clinical Protocols ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - mortality ; Coronary Artery Disease - therapy ; Exercise Test ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Myocardial Revascularization ; Patient Selection ; Perioperative Care ; Platelet Aggregation Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Predictive Value of Tests ; Preoperative Care ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Risk Assessment ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; United States ; Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels ; Vascular Surgical Procedures - adverse effects ; Vascular Surgical Procedures - mortality</subject><ispartof>Journal of vascular surgery, 2010, Vol.51 (1), p.242-251</ispartof><rights>Society for Vascular Surgery</rights><rights>2010 Society for Vascular Surgery</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-519099cb9d2982f9723eaaf4049d99992a524b9ee0152fe2dd0c5dca6b8b793a3</citedby><cites>FETCH-LOGICAL-c480t-519099cb9d2982f9723eaaf4049d99992a524b9ee0152fe2dd0c5dca6b8b793a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0741521409018199$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22323347$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19954922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bauer, Stephen M., MD</creatorcontrib><creatorcontrib>Cayne, Neal S., MD</creatorcontrib><creatorcontrib>Veith, Frank J., MD</creatorcontrib><title>New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery</title><title>Journal of vascular surgery</title><addtitle>J Vasc Surg</addtitle><description>Background Preoperative evaluation and perioperative management of cardiac disease in patients undergoing vascular surgery (VS) is important for patients and vascular surgeons. Recent evidence has emerged that has allowed us to develop contemporary paradigms for evaluating and managing coronary artery disease in VS patients perioperatively. Methods The utility of stress testing, the role of preoperative coronary revascularization, the optimal use of β-blockers and statins, and the role of antiplatelet therapy in VS patients were reviewed in the literature. Results The revised Lee cardiac risk index, based on the number of risk factors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-dependent diabetes mellitus, renal failure, hypertension, and age >75) quantitates cardiac risk. Stress testing is not predictive of myocardial ischemia/infarction (MI) or death and is only recommended in patients with unstable angina or an active arrhythmia. Stress testing for patients with 0 to 2 risk factors delays VS up to 3 weeks. In high-risk patients (≥3 risk factors), it helps to identify patients who may develop myocardial ischemia and would benefit from a 30-day period to optimize medical therapy before VS. Stress testing and coronary catheterization do not predict which coronary artery to revascularize to prevent MI or death. Revascularization does not decrease MI or death rates at 1 month or 6 years. Although β-blocker treatment decreases cardiac risk with VS, timing and dosage (titration) influence outcomes, improper usage may increase stroke and death rate, and not all VS patients should be taking these drugs. Patients with ≥1 risk factor should be considered to begin a low dose β-blocker 1 month before VS. Preoperative statin use sharply decreases MI, stroke, and death perioperatively and long-term postoperatively. Conclusion Routine stress testing should not be performed before VS. The Lee index should be used to stratify risk in patients undergoing VS. Patients with ≥3 risk factors or active cardiac conditions should undergo stress testing, if VS can be delayed. All VS patients, except those with 0 risk factors, should be considered for a β-blocker (bisoprolol, 2.5-5 mg/d started 1 month before VS, titrated to a pulse <70 beats/min and a systolic blood pressure ≥120 mm Hg). Intermediate risk factors may not require aggressive heart rate control but simply maintenance on a low-dose β-blocker. Statins should be started (ideally 30 days) before all VS using long-acting formulations such as fluvastatin (80 mg/d) for patients unable to take oral medication.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Algorithms</subject><subject>American Heart Association</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cardiovascular system</subject><subject>Clinical Protocols</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Coronary Artery Disease - mortality</subject><subject>Coronary Artery Disease - therapy</subject><subject>Exercise Test</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Myocardial Revascularization</subject><subject>Patient Selection</subject><subject>Perioperative Care</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Predictive Value of Tests</subject><subject>Preoperative Care</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>United States</subject><subject>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</subject><subject>Vascular Surgical Procedures - adverse effects</subject><subject>Vascular Surgical Procedures - mortality</subject><issn>0741-5214</issn><issn>1097-6809</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt2K1TAQgIso7nH1AbyR3IhXPU7S9rRBEJbFP1j0Qr0OaTI9prZJTdrKPoWv7NRzcMELw8CE5Jv_ybKnHPYc-OFlv-_XtBcAcg8NSX0v23GQdX5oQN7PdlCXPK8ELy-yRyn1AJxXTf0wu-BSVqUUYpf9-og_mcUVhzCN6OfEnGfzN2RTxDBh1LNbkeGqh4WuwTPtLaN3d_c5aq-PuBmz0DETYvA63jIdZyRlXUKdcHM7Ef8nxOItxmNw_shWncwy6MjSEo_EP84edHpI-OSsL7Ovb998uX6f33x69-H66iY3ZQNzXnEJUppWWiEb0claFKh1V0IpraQjdCXKViICr0SHwlowlTX60DZtLQtdXGYvTn6nGH4smGY1umRwGLTHsCRVF6U4VBVIIvmJNDGkFLFTU3QjVag4qG0Mqlc0BrWNQUFDUpPNs7P3pR3R3lmc-07A8zNA9euhi9obl_5yRIiiKDdHr04cUi9Wh1ElQz00aF1EMysb3H_TeP2PtRmcdxTwO95i6sMSPTVZcZWEAvV525dtXUACbyjX4jepxb6g</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Bauer, Stephen M., MD</creator><creator>Cayne, Neal S., MD</creator><creator>Veith, Frank J., MD</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery</title><author>Bauer, Stephen M., MD ; Cayne, Neal S., MD ; Veith, Frank J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-519099cb9d2982f9723eaaf4049d99992a524b9ee0152fe2dd0c5dca6b8b793a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Algorithms</topic><topic>American Heart Association</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cardiovascular system</topic><topic>Clinical Protocols</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Coronary Artery Disease - mortality</topic><topic>Coronary Artery Disease - therapy</topic><topic>Exercise Test</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Myocardial Revascularization</topic><topic>Patient Selection</topic><topic>Perioperative Care</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Predictive Value of Tests</topic><topic>Preoperative Care</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>United States</topic><topic>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</topic><topic>Vascular Surgical Procedures - adverse effects</topic><topic>Vascular Surgical Procedures - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, Stephen M., MD</creatorcontrib><creatorcontrib>Cayne, Neal S., MD</creatorcontrib><creatorcontrib>Veith, Frank J., MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, Stephen M., MD</au><au>Cayne, Neal S., MD</au><au>Veith, Frank J., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery</atitle><jtitle>Journal of vascular surgery</jtitle><addtitle>J Vasc Surg</addtitle><date>2010</date><risdate>2010</risdate><volume>51</volume><issue>1</issue><spage>242</spage><epage>251</epage><pages>242-251</pages><issn>0741-5214</issn><eissn>1097-6809</eissn><coden>JVSUES</coden><abstract>Background Preoperative evaluation and perioperative management of cardiac disease in patients undergoing vascular surgery (VS) is important for patients and vascular surgeons. Recent evidence has emerged that has allowed us to develop contemporary paradigms for evaluating and managing coronary artery disease in VS patients perioperatively. Methods The utility of stress testing, the role of preoperative coronary revascularization, the optimal use of β-blockers and statins, and the role of antiplatelet therapy in VS patients were reviewed in the literature. Results The revised Lee cardiac risk index, based on the number of risk factors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-dependent diabetes mellitus, renal failure, hypertension, and age >75) quantitates cardiac risk. Stress testing is not predictive of myocardial ischemia/infarction (MI) or death and is only recommended in patients with unstable angina or an active arrhythmia. Stress testing for patients with 0 to 2 risk factors delays VS up to 3 weeks. In high-risk patients (≥3 risk factors), it helps to identify patients who may develop myocardial ischemia and would benefit from a 30-day period to optimize medical therapy before VS. Stress testing and coronary catheterization do not predict which coronary artery to revascularize to prevent MI or death. Revascularization does not decrease MI or death rates at 1 month or 6 years. Although β-blocker treatment decreases cardiac risk with VS, timing and dosage (titration) influence outcomes, improper usage may increase stroke and death rate, and not all VS patients should be taking these drugs. Patients with ≥1 risk factor should be considered to begin a low dose β-blocker 1 month before VS. Preoperative statin use sharply decreases MI, stroke, and death perioperatively and long-term postoperatively. Conclusion Routine stress testing should not be performed before VS. The Lee index should be used to stratify risk in patients undergoing VS. Patients with ≥3 risk factors or active cardiac conditions should undergo stress testing, if VS can be delayed. All VS patients, except those with 0 risk factors, should be considered for a β-blocker (bisoprolol, 2.5-5 mg/d started 1 month before VS, titrated to a pulse <70 beats/min and a systolic blood pressure ≥120 mm Hg). Intermediate risk factors may not require aggressive heart rate control but simply maintenance on a low-dose β-blocker. Statins should be started (ideally 30 days) before all VS using long-acting formulations such as fluvastatin (80 mg/d) for patients unable to take oral medication.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>19954922</pmid><doi>10.1016/j.jvs.2009.08.087</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-5214 |
| ispartof | Journal of vascular surgery, 2010, Vol.51 (1), p.242-251 |
| issn | 0741-5214 1097-6809 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734265509 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenergic beta-Antagonists - therapeutic use Algorithms American Heart Association Biological and medical sciences Cardiovascular Agents - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular system Clinical Protocols Coronary Artery Disease - complications Coronary Artery Disease - diagnosis Coronary Artery Disease - mortality Coronary Artery Disease - therapy Exercise Test Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Investigative techniques, diagnostic techniques (general aspects) Medical sciences Myocardial Revascularization Patient Selection Perioperative Care Platelet Aggregation Inhibitors - therapeutic use Practice Guidelines as Topic Predictive Value of Tests Preoperative Care Radiodiagnosis. Nmr imagery. Nmr spectrometry Risk Assessment Risk Factors Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases United States Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels Vascular Surgical Procedures - adverse effects Vascular Surgical Procedures - mortality |
| title | New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A09%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20developments%20in%20the%20preoperative%20evaluation%20and%20perioperative%20management%20of%20coronary%20artery%20disease%20in%20patients%20undergoing%20vascular%20surgery&rft.jtitle=Journal%20of%20vascular%20surgery&rft.au=Bauer,%20Stephen%20M.,%20MD&rft.date=2010&rft.volume=51&rft.issue=1&rft.spage=242&rft.epage=251&rft.pages=242-251&rft.issn=0741-5214&rft.eissn=1097-6809&rft.coden=JVSUES&rft_id=info:doi/10.1016/j.jvs.2009.08.087&rft_dat=%3Cproquest_cross%3E734265509%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734265509&rft_id=info:pmid/19954922&rft_els_id=S0741521409018199&rfr_iscdi=true |